Biblio
Export 19 results:
Author Title Type [ Year
Filters: Author is Engelborghs, Sebastiaan [Clear All Filters]
“Improved Alzheimer's Disease versus Frontotemporal Lobar Degeneration Differential Diagnosis Combining EEG and Neurochemical Biomarkers: A Pilot Study.”, J Alzheimers Dis, vol. 90, no. 4, pp. 1739-1747, 2022.
, “Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 80, no. 4, pp. 1629-1642, 2021.
, “Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 77, no. 3, pp. 1353-1368, 2020.
, “Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort.”, J Alzheimers Dis, vol. 74, no. 1, pp. 213-225, 2020.
, “Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort.”, J Alzheimers Dis, vol. 63, no. 1, pp. 373-381, 2018.
, “Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis.”, J Alzheimers Dis, vol. 62, no. 3, pp. 1199-1209, 2018.
, “A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer's Disease (REMEMBER).”, J Alzheimers Dis, vol. 63, no. 4, pp. 1509-1522, 2018.
, “BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants.”, J Alzheimers Dis, vol. 56, no. 4, pp. 1437-1449, 2017.
, “The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.”, J Alzheimers Dis, vol. 60, no. 2, pp. 561-576, 2017.
, “Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.”, J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
, “EEG Dominant Frequency Peak Differentiates Between Alzheimer's Disease and Frontotemporal Lobar Degeneration.”, J Alzheimers Dis, vol. 55, no. 1, pp. 53-58, 2017.
, “Neutrophil Gelatinase-Associated Lipocalin and its Receptors in Alzheimer's Disease (AD) Brain Regions: Differential Findings in AD with and without Depression.”, J Alzheimers Dis, vol. 55, no. 2, pp. 763-776, 2017.
, “Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization.”, J Alzheimers Dis, vol. 55, no. 1, pp. 159-170, 2017.
, “The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1523-38, 2016.
, “Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.”, J Alzheimers Dis, vol. 52, no. 1, pp. 51-64, 2016.
, “A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.”, J Alzheimers Dis, vol. 54, no. 1, pp. 383-95, 2016.
, “Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 97-106, 2016.
, “Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study.”, J Alzheimers Dis, vol. 52, no. 4, pp. 1321-33, 2016.
, “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
,